We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

New late-stage study data shows that treatment with Amgen's Uplizna for a year improves disease symptoms in patients with ...

The phase 3 MINT trial evaluated the efficacy and safety of the drug in both muscle-specific kinase autoantibody ...

Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire ...

A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...

Rare diseases - a medical condition so obscure that even your doctor has to Google. Despite their name, these diseases ...

New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...

The bioengineered protein drugs market is experiencing a paradigm shift, with pharmaceutical and biotech companies leveraging advanced biopharmaceuti ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...

The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...

Samsung Bioepis Co. and Celltrion Inc. are outpacing long-established global drug manufacturers such as Amgen Inc. and Sandoz ...